##plugins.themes.vojs.article.sidebar##

Published: 2025-08-22
Abstract Views: 8
Issue
Vol. 18 No. 1 (2025)
Section
Research

HEMATOLOGICAL ADVERSE EVENTS ASSOCIATED WITH LINEZOLID USE IN CHILDREN AT VIETNAM NATIONAL CHILDREN’S HOSPITAL

Nhat Minh Tran1, Thu Ha Pham1, Quoc Anh Phan2, Thi Phuong Thuy Do2, Thi Hong Ha Nguyen1,2
1 Vietnam National Children’s Hospital
2 University of Medicine and Pharmacy, Vietnam National University, Hanoi

##plugins.themes.vojs.article.main##

Abstract

Objectives: Describe the prevalence of linezolid-associated hematological adverse events at Vietnam National Children’s Hospital (VNCH) and their associated factors.
Methods: Retrospective. 163 under-18-year-old patients who used linezolid at VNCH from 06/2022 to 12/2022 were included. The association between hematological adverse events and patient and drug use factors was assessed.


Results: The prevalences of linezolid-related anemia, thrombocytopenia and neutropenia were 6.5%, 12.1% and 6.0% respectively. The onset time for the adverse events was 6 to10 days after linezolid initiation. Linezolid length of use (OR 1.073; p 0.023) and concomitant use of heparin (OR 8.684; p 0.005) were independently associated with linezolid-related thrombocytopenia. Linezolid length of use (OR 1.092; 0.023) and baseline neutrophil count (OR 0.742; p 0.005) were signifcantly associated with linezolid-related neutropenia

##plugins.themes.vojs.article.details##

Keywords

linezolid, thrombocytopenia, anemia, neutropenia

References

1. FDA. Zyvox Approval Dates and History: Drugs@FDA; 2024 [Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021131.
2. Kato H, Hagihara M, Asai N et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist 2021;24:98-105. https://doi.org/10.1016/j.jgar.2020.12.009
3. Pfzer. Tờ thông tin sản phẩm Zyvox. 2024.
4. Kato H, Hagihara M, Asai N et al. A systematic review and meta-analysis of myelosuppression in pediatric patients treated with linezolid for Gram-positive bacterial infections. J Infect Chemother 2021;27(8):1143-1150.
5. Shi Y, Wu HL, Wu YH et al. Safety and clinical efcacy of linezolid in children: a systematic review and meta-analysis. World J Pediatr 2023;19(2):129-138.https://doi.org/10.1007/s12519-022-00650-1
6. Khoa Dược. Báo cáo Sử dụng thuốc. Hà Nội: Bệnh viện Nhi Trung ương; 2022.
7. Huệ NT, Thảo NTP, Hằng BT. Sổ tay khoảng tham chiếu. Hà Nội: Bệnh viện Nhi Trung ương; 2023.
8. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0.2017.
9. Centre Uppsala Monitoring. The use of the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) system for standardised case causality assessment 2006 [Available from: https://cdn.who.int/media/docs/default-source/medicines/phar macovigilance/whocausality-assessment.pdf.
10. Brown NM, Goodman AL, Horner C et al. Treatment of methicillin-resistant taphylococcus aureus (MRSA): updated guidelines from the UK. JAC-Antimicrobial Resistance 2021;3(1):dlaa114. https://doi.org/10.1093/jacamr/dlaa114
11. Jones SJ, Nichols KR, DeYoung HL et al.Linezolid-Associated Thrombocytopenia in Children With Renal Impairment. J Pediatric Infect Dis Soc 2015;4(3):272-275.https://doi.org/10.1093/jpids/piu035